Over the last decade, the biotech sector experienced the largest boom it has ever seen. Yet in just a few months in 2022, there has been a sharp reversal in the tone of capital markets towards biotech and beyond, plunging the industry into a bear market.
Having worked in the life sciences industry for the last 20-plus years in operational roles as a CFO and advisory roles as an investment banker, I know firsthand that bear markets can put a damper on the industry’s pace of innovation in the short term. But I’ve also learned that, with the right approach, companies can make the best of a bad situation to sharpen their focus and set the stage for a stronger trajectory on the other side.
Create a display name to comment
This name will appear with your comment